Intech Investment Management LLC Buys 15,167 Shares of PTC Therapeutics, Inc. $PTCT

Intech Investment Management LLC raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 62.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,307 shares of the biopharmaceutical company’s stock after acquiring an additional 15,167 shares during the quarter. Intech Investment Management LLC’s holdings in PTC Therapeutics were worth $2,003,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in PTC Therapeutics by 0.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,681 shares of the biopharmaceutical company’s stock valued at $2,967,000 after acquiring an additional 205 shares in the last quarter. Xponance Inc. boosted its position in shares of PTC Therapeutics by 5.2% in the 1st quarter. Xponance Inc. now owns 6,372 shares of the biopharmaceutical company’s stock worth $325,000 after purchasing an additional 314 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of PTC Therapeutics by 84.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 320 shares in the last quarter. Diversified Trust Co boosted its position in shares of PTC Therapeutics by 2.0% in the 1st quarter. Diversified Trust Co now owns 17,147 shares of the biopharmaceutical company’s stock worth $874,000 after purchasing an additional 329 shares in the last quarter. Finally, GF Fund Management CO. LTD. boosted its position in shares of PTC Therapeutics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,974 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 355 shares in the last quarter.

PTC Therapeutics Stock Performance

NASDAQ PTCT opened at $59.69 on Wednesday. The stock has a 50-day simple moving average of $50.73 and a two-hundred day simple moving average of $49.57. The firm has a market capitalization of $4.74 billion, a P/E ratio of 8.56 and a beta of 0.53. PTC Therapeutics, Inc. has a fifty-two week low of $33.88 and a fifty-two week high of $62.18.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.24. The business had revenue of $178.88 million during the quarter, compared to analyst estimates of $173.01 million. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The company’s revenue was down 4.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.29) EPS. PTC Therapeutics has set its FY 2025 guidance at EPS. As a group, analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Insider Transactions at PTC Therapeutics

In related news, VP Mark Elliott Boulding sold 24,585 shares of PTC Therapeutics stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $61.34, for a total value of $1,508,043.90. Following the completion of the transaction, the vice president owned 103,901 shares in the company, valued at $6,373,287.34. The trade was a 19.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David P. Southwell sold 12,000 shares of PTC Therapeutics stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $58.34, for a total value of $700,080.00. Following the completion of the transaction, the director owned 16,850 shares of the company’s stock, valued at approximately $983,029. This represents a 41.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 131,393 shares of company stock worth $7,640,615 over the last quarter. Company insiders own 5.50% of the company’s stock.

Analyst Upgrades and Downgrades

PTCT has been the subject of a number of recent analyst reports. Robert W. Baird set a $70.00 price objective on PTC Therapeutics in a research report on Friday, August 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price objective on shares of PTC Therapeutics in a research report on Wednesday, September 3rd. UBS Group raised their price objective on PTC Therapeutics from $71.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. Citigroup raised their price objective on PTC Therapeutics from $40.00 to $50.00 and gave the stock a “neutral” rating in a research report on Monday, July 28th. Finally, Wall Street Zen cut PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 9th. Nine equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, PTC Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $69.00.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.